Deloitte Corporate Finance LLC Advises Diamondback Drugs of Delaware, LLC in its Sale to Tailwind Capital

CHARLOTTE, N.C., Dec. 22, 2014 /PRNewswire/ -- Deloitte Corporate Finance LLC ("DCF") acted as exclusive financial advisor to Diamondback Drugs of Delaware, LLC ("Diamondback Drugs" or "Company"), a portfolio company of Sheridan Legacy Group, LLC ("Sheridan Legacy"), in its sale to Tailwind Capital. Diamondback Drugs is a national specialty veterinary pharmacy operating throughout the United States.

Sheridan Legacy invested in Diamondback Drugs in 2012, when it partnered with the Company's founders. Dave Vorhoff, managing director for Deloitte Corporate Finance LLC, along with other DCF professionals advised Diamondback in the 2012 transaction with Sheridan Legacy while at a predecessor firm.

"We were pleased to execute on a number of strategic initiatives under the leadership of Sheridan Legacy and look forward to our partnership with Tailwind Capital," said Michael Blaire, CEO of Diamondback Drugs.

"DCF's strong appreciation of the subtleties of the industry landscape in which the Company operates created significant value to all shareholders throughout the entire sale process. Their process identified the most reliable buyer but more importantly, the most knowledgeable and best suited partner for the Company's next phase of growth. It was a pleasure working with their team," said Jonathan Lewis, managing principal and partner for Sheridan Legacy Group.

"Advising Diamondback Drugs for the second time marks the fifth deal we've closed in this niche space during the past 24 months," said Dave Vorhoff, managing director for Deloitte Corporate Finance LLC. "Since making its investment in the Company in 2012, Sheridan Legacy actively worked with Diamondback Drugs' management team to enhance the value proposition to veterinarians and pet owners, yielding results that attracted a number of potential suitors for the business."

About Diamondback Drugs of Delaware, LLC

Diamondback Drugs is a national specialty veterinary pharmacy, serving veterinary clinics, veterinary hospitals, aquariums and zoos, research institutions, and individual animal owners. Diamondback Drugs' products are tailor-made for the specific pet-patient in need, allowing for greater flexibility in treatment. Since 2001, Diamondback Drugs' products have been treating veterinary patients across the nation for a variety of ailments using a multitude of dosage forms including injectables, tablets, and chewables. For more information about Diamondback Drugs and its products, visit www.diamondbackdrugs.com.

About Sheridan Legacy Group, LLC

Founded in 2012, Sheridan Legacy Group, LLC is a private equity investment firm based in Chicago, Illinois. Sheridan Legacy prefers to invest in small and medium sized companies to partner with exceptional managers, entrepreneurs, and owners. Industry sectors of interest for Sheridan Legacy include Healthcare and Consumer products. More information about Sheridan Legacy can be found at www.sheridanlegacy.com.

About Tailwind Capital

Founded in 2003, Tailwind Capital is a leading private equity firm focused on making control-oriented investments in the lower end of the middle market and transforming businesses through organic growth, acquisitions, and operational and strategic improvements. Tailwind targets niche businesses in the Healthcare, Business and Communications Services sectors. For further information, please visit: www.tailwind.com.

About Deloitte Corporate Finance LLC
Deloitte Corporate Finance LLC (DCF) provides strategic advisory services and M&A advice that help corporate, entrepreneurial and private equity clients create and act upon opportunities for liquidity, growth and long-term advantage. With an in-depth understanding of the marketplace and access to a global network of investment bankers, we help clients confidently pursue strategic transactions in both domestic and global markets. DCF, together with the Corporate Finance Advisory practices within the Deloitte Touche Tohmatsu Limited network of member firms, include in excess of 1,900 professionals, who work collaboratively across 150 international locations. With our significant experience providing investment banking services across key industries, we are able to offer our clients solutions that help them to achieve their strategic objectives. For more information, visit www.investmentbanking.deloitte.com.

Prior engagement performance is no guarantee of future performance and may not be representative of the experience of other clients. This communication is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security.

Deloitte Corporate Finance LLC, an SEC registered broker-dealer and member of FINRA and SIPC, is an indirect wholly-owned subsidiary of Deloitte Financial Advisory Services LLP and affiliate of Deloitte Transactions and Business Analytics LLP. Investment banking products and services within the United States are offered exclusively through Deloitte Corporate Finance LLC. For more information, visit www.investmentbanking.deloitte.com. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Logo - http://photos.prnewswire.com/prnh/20120803/MM52028LOGO-a

SOURCE Deloitte

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…